blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3437654

EP3437654 - PHARMACEUTICAL COMPOSITION THAT INCLUDES THE SURFACE AND NUCLEOCAPSID ANTIGENS OF THE HEPATITIS B VIRUS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  26.07.2024
Database last updated on 11.04.2026
FormerThe patent has been granted
Status updated on  18.08.2023
FormerGrant of patent is intended
Status updated on  19.04.2023
FormerExamination is in progress
Status updated on  05.06.2020
FormerRequest for examination was made
Status updated on  04.01.2019
FormerThe international publication has been made
Status updated on  07.10.2017
Formerunknown
Status updated on  16.05.2017
Most recent event   Tooltip05.09.2025Lapse of the patent in a contracting state
New state(s): HU		published on 08.10.2025  [2025/41]
Applicant(s)For all designated states
Centro De Ingeniería Genética Y Biotecnología
Avenida 31 entre 158 y 190.
Cubanacán, Playa
11600 La Habana / CU
[2019/06]
Inventor(s)01 / AGUILAR RUBIDO, Julio, Cesar
Calle 186, No. 3112
Entre 31 y 33, Apto 3
Planta Baja
Cubanacán. PIaya.
La Habana 11600 / CU
02 / LOBAINA MATO, Yadira
Calle 186
No 3117
Apto 12J
e/ 31 y 33, Cubanacán, Playa
La Habana 11600 / CU
03 / IGLESIAS PEREZ, Enrique
Edif. 25 Apto 103
Reparto Camilo
Cienfuegos
Habana del Este
La Habana 10900 / CU
04 / PENTON ARIAS, Eduardo
Ave 31 No 18207
Apto 49
e/ 182 y 184
Playa
La Habana 11600 / CU
05 / GUILLEN NIETO, Gerardo, Enrique
Ave. 31 No. 18207
Piso 9
Apto 34
e/ 182 y 186, Playa
La Habana 11600 / CU
06 / AGUIAR SANTIAGO, Jorge, Agustin
Calle 186
Edificio 3117
Apto F (piso 5)
e/ Avenida 31 y Avenida 33, Playa
La Habana 11600 / CU
07 / GONZALEZ BLANCO, Sonia
Calle 186
Edificio 3112 Apto 42
ente Avenida 31 y Avenida 33
Playa
La Habana 11600 / CU
08 / VALDES HERNANDEZ, Jorge
Calle 184 No. 3112
Apto. 17
entre 31 y 33
Playa La Habana 11600 / CU
09 / VAZQUEZ CASTILLO, Mariela
Calle 186 Edificio 3112
Apto 32 Entre Avenida 31 y
Avenida 33
Playa
La Habana 11600 / CU
 [2023/38]
Former [2019/06]01 / AGUILAR RUBIDO, Julio, Cesar
Calle 186, No. 3112
Entre 31 y 33, Apto 3
Planta Baja
Cubanacán. PIaya.
La Habana 11600 / CU
02 / LOBAINA MATO, Yadira
Calle 186
No 3117
Apto 12J
e/ 31 y 33, Cubanacán, Playa
La Habana 11600 / CU
03 / IGLESIAS PEREZ, Enrique
Edif. 25 Apto 103
Reparto Camilo
Cienfuegos
Habana del Este
La Habana 10900 / CU
04 / PENTON ARIAS, Eduardo
Ave 31 No 18207
Apto 49
e/ 182 y 184
Playa
La Habana 11600 / CU
05 / GUILLEN NIETO, Gerardo, Enrique
Ave. 31 No. 18207
Piso 9
Apto 34
e/ 182 y 186, Playa
La Habana 11600 / CU
06 / AGUIAR SANTIAGO, Jorge, Agustin
Calle 186
Edificio 3117
Apto F (piso 5)
e/ Avenida 31 y Avenida 33, Playa
La Habana 11600 / CU
07 / GONZALEZ BLANCO, Sonia
Calle 186
Edificio 3112 Apto 42
ente Avenida 31 y Avenida 33
Playa
La Habana 11600 / CU
08 / VALDES HERNANDEZ, Jorge
Calle 35 No.194
Apto 29
e/ Loma y 6
Nuevo Vedado, Plaza
La Habana 10600 / CU
09 / VAZQUEZ CASTILLO, Mariela
Calle 186 Edificio 3112
Apto 32 Entre Avenida 31 y
Avenida 33
Playa
La Habana 11600 / CU
Representative(s)V.O.
P.O. Box 87930
Carnegieplein 5
2508 DH Den Haag / NL
[2019/06]
Application number, filing date17721509.214.03.2017
[2019/06]
WO2017CU50001
Priority number, dateCU2016000003831.03.2016         Original published format: CU 20160038
[2019/06]
Filing languageES
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2017167317
Date:05.10.2017
Language:ES
[2017/40]
Type: A1 Application with search report 
No.:EP3437654
Date:06.02.2019
Language:EN
[2019/06]
Type: B1 Patent specification 
No.:EP3437654
Date:20.09.2023
Language:EN
[2023/38]
Search report(s)International search report - published on:EP05.10.2017
ClassificationIPC:A61K39/12, C07K14/005
[2019/06]
CPC:
A61K39/12 (EP,EA); A61K39/292 (KR,US); A61K39/39 (US);
A61P1/16 (EP); A61P31/20 (EP,US); A61P35/00 (EP);
A61P37/04 (EP); C07K14/005 (EP,EA); A61K2039/5258 (EP,EA,KR,US);
A61K2039/543 (EP,EA,KR,US); A61K2039/555 (US); A61K2039/55505 (EP,EA,KR);
A61K2039/57 (EP,EA,KR); A61K2039/575 (EP,EA,KR,US); C12N2730/10123 (EP,EA,KR);
C12N2730/10134 (EP,EA,KR) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/06]
Extension statesBA19.10.2018
ME19.10.2018
Validation statesMD19.10.2018
TitleGerman:COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE LOS ANTÍGENOS DE LA SUPERFICIE Y DE LA NUCLEOCÁPSIDA DEL VIRUS DE LA HEPATITIS B[2023/15]
English:PHARMACEUTICAL COMPOSITION THAT INCLUDES THE SURFACE AND NUCLEOCAPSID ANTIGENS OF THE HEPATITIS B VIRUS[2019/06]
French:COMPOSITION PHARMACEUTIQUE QUI COMPREND LES ANTIGÈNES DE LA SURFACE ET DE LA NUCLÉOCAPSIDE DU VIRUS DE L'HÉPATITE B[2019/06]
Former [2019/06]PHARMAZEUTISCHE ZUSAMMENSETZUNG MIT OBERFLÄCHEN- UND NUKLEOKAPSID-ANTIGENEN DES HEPATITIS-B-VIRUS
Entry into regional phase19.10.2018Translation filed 
19.10.2018National basic fee paid 
19.10.2018Designation fee(s) paid 
19.10.2018Examination fee paid 
Examination procedure19.10.2018Amendment by applicant (claims and/or description)
19.10.2018Examination requested  [2019/06]
19.10.2018Date on which the examining division has become responsible
09.06.2020Despatch of a communication from the examining division (Time limit: M06)
18.12.2020Reply to a communication from the examining division
07.09.2022Despatch of a communication from the examining division (Time limit: M06)
02.02.2023Reply to a communication from the examining division
07.03.2023Despatch of a communication from the examining division (Time limit: M02)
08.03.2023Reply to a communication from the examining division
20.04.2023Communication of intention to grant the patent
15.08.2023Fee for grant paid
15.08.2023Fee for publishing/printing paid
15.08.2023Receipt of the translation of the claim(s)
Opposition(s)21.06.2024No opposition filed within time limit [2024/35]
Fees paidRenewal fee
19.02.2019Renewal fee patent year 03
18.02.2020Renewal fee patent year 04
24.08.2021Renewal fee patent year 05
22.02.2022Renewal fee patent year 06
17.01.2023Renewal fee patent year 07
Penalty fee
Additional fee for renewal fee
31.03.202105   M06   Fee paid on   24.08.2021
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCY14.03.2017
HU14.03.2017
AT20.09.2023
BG20.09.2023
CZ20.09.2023
DK20.09.2023
EE20.09.2023
FI20.09.2023
HR20.09.2023
LT20.09.2023
LV20.09.2023
MC20.09.2023
PL20.09.2023
RO20.09.2023
RS20.09.2023
SE20.09.2023
SI20.09.2023
SK20.09.2023
SM20.09.2023
NO20.12.2023
GR21.12.2023
IS20.01.2024
PT22.01.2024
LU14.03.2024
BE31.03.2024
[2025/41]
Former [2025/37]CY14.03.2017
AT20.09.2023
BG20.09.2023
CZ20.09.2023
DK20.09.2023
EE20.09.2023
FI20.09.2023
HR20.09.2023
LT20.09.2023
LV20.09.2023
MC20.09.2023
PL20.09.2023
RO20.09.2023
RS20.09.2023
SE20.09.2023
SI20.09.2023
SK20.09.2023
SM20.09.2023
NO20.12.2023
GR21.12.2023
IS20.01.2024
PT22.01.2024
LU14.03.2024
BE31.03.2024
Former [2025/08]AT20.09.2023
BG20.09.2023
CZ20.09.2023
DK20.09.2023
EE20.09.2023
FI20.09.2023
HR20.09.2023
LT20.09.2023
LV20.09.2023
MC20.09.2023
PL20.09.2023
RO20.09.2023
RS20.09.2023
SE20.09.2023
SI20.09.2023
SK20.09.2023
SM20.09.2023
NO20.12.2023
GR21.12.2023
IS20.01.2024
PT22.01.2024
LU14.03.2024
BE31.03.2024
Former [2024/52]AT20.09.2023
BG20.09.2023
CZ20.09.2023
DK20.09.2023
EE20.09.2023
FI20.09.2023
HR20.09.2023
LT20.09.2023
LV20.09.2023
MC20.09.2023
PL20.09.2023
RO20.09.2023
RS20.09.2023
SE20.09.2023
SI20.09.2023
SK20.09.2023
SM20.09.2023
NO20.12.2023
GR21.12.2023
IS20.01.2024
PT22.01.2024
LU14.03.2024
Former [2024/51]AT20.09.2023
BG20.09.2023
CZ20.09.2023
DK20.09.2023
EE20.09.2023
FI20.09.2023
HR20.09.2023
LT20.09.2023
LV20.09.2023
PL20.09.2023
RO20.09.2023
RS20.09.2023
SE20.09.2023
SI20.09.2023
SK20.09.2023
SM20.09.2023
NO20.12.2023
GR21.12.2023
IS20.01.2024
PT22.01.2024
Former [2024/49]AT20.09.2023
CZ20.09.2023
DK20.09.2023
EE20.09.2023
FI20.09.2023
HR20.09.2023
LT20.09.2023
LV20.09.2023
PL20.09.2023
RO20.09.2023
RS20.09.2023
SE20.09.2023
SI20.09.2023
SK20.09.2023
SM20.09.2023
NO20.12.2023
GR21.12.2023
IS20.01.2024
PT22.01.2024
Former [2024/33]AT20.09.2023
CZ20.09.2023
DK20.09.2023
EE20.09.2023
FI20.09.2023
HR20.09.2023
LT20.09.2023
LV20.09.2023
PL20.09.2023
RO20.09.2023
RS20.09.2023
SE20.09.2023
SK20.09.2023
SM20.09.2023
NO20.12.2023
GR21.12.2023
IS20.01.2024
PT22.01.2024
Former [2024/25]AT20.09.2023
CZ20.09.2023
EE20.09.2023
FI20.09.2023
HR20.09.2023
LT20.09.2023
LV20.09.2023
PL20.09.2023
RO20.09.2023
RS20.09.2023
SE20.09.2023
SK20.09.2023
SM20.09.2023
NO20.12.2023
GR21.12.2023
IS20.01.2024
PT22.01.2024
Former [2024/23]AT20.09.2023
CZ20.09.2023
EE20.09.2023
FI20.09.2023
HR20.09.2023
LT20.09.2023
LV20.09.2023
RO20.09.2023
RS20.09.2023
SE20.09.2023
SK20.09.2023
SM20.09.2023
NO20.12.2023
GR21.12.2023
IS20.01.2024
PT22.01.2024
Former [2024/20]FI20.09.2023
HR20.09.2023
LT20.09.2023
LV20.09.2023
RS20.09.2023
SE20.09.2023
SM20.09.2023
NO20.12.2023
GR21.12.2023
IS20.01.2024
Former [2024/10]FI20.09.2023
HR20.09.2023
LT20.09.2023
LV20.09.2023
RS20.09.2023
SE20.09.2023
NO20.12.2023
GR21.12.2023
Former [2024/09]FI20.09.2023
LT20.09.2023
SE20.09.2023
NO20.12.2023
GR21.12.2023
Former [2024/08]LT20.09.2023
NO20.12.2023
GR21.12.2023
Cited inInternational search[Y] EP2484343  (CT INGENIERIA GENETICA BIOTECH et al.)
 [XI]   BENG TI TEY ET AL: "Optimal conditions for hepatitis B core antigen production in shaked flask fermentation", BIOTECHNOLOGY AND BIOPROCESS ENGINEERING, vol. 9, no. 5, 1 October 2004 (2004-10-01), KR, pages 374 - 378, XP055385266, ISSN: 1226-8372, DOI: 10.1007/BF02933060

DOI:   http://dx.doi.org/10.1007/BF02933060
 [XI]   DANIEL O PALENZUELA ET AL: "Purification of the Recombinant Hepatitis B Core Antigen, and Its Potential Use for the Diagnosis of Hepatitis B Virus Infection", BIOTECNOLOGA APLICADA, vol. 19, no. 3-4, 1 January 2002 (2002-01-01), CU, pages 138 - 142, XP055385221, ISSN: 0864-4551
 [YD]   Y LOBAINA ET AL: "Comparison of the immune response induced in mice by five commercial vaccines based on recombinant HBsAg from different sources, implications on their therapeutic use", BIOTECNOLOGA APLICADA, vol. 25, no. 4, 1 January 2008 (2008-01-01), CU, pages 325 - 331, XP055385126, ISSN: 0864-4551
 [YD]   AGUILAR J C ET AL: "Development of a nasal vaccine for chronic hepatitis B infection that uses the ability of hepatitis B core antigen to stimulate a strong Th1 response against hepatitis B surface antigen", IMMUNOLOGY AND CELL BIOLOGY, CARLTON, AU, vol. 82, no. 5, 1 October 2004 (2004-10-01), pages 539 - 546, XP002354413, ISSN: 0818-9641, DOI: 10.1111/J.0818-9641.2004.01278.X

DOI:   http://dx.doi.org/10.1111/j.0818-9641.2004.01278.x
 [Y]   BETANCOURT ET AL: "Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens", INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, INTERNATIONAL SOCIETY FOR INFECTIOUS DISEASES, HAMILTON, CA, vol. 11, no. 5, 14 August 2007 (2007-08-14), pages 394 - 401, XP022200686, ISSN: 1201-9712, DOI: 10.1016/J.IJID.2006.09.010

DOI:   http://dx.doi.org/10.1016/j.ijid.2006.09.010
 [Y]   RIEDL P ET AL: "Priming Th1 immunity to viral core particles is facilitated by trace amounts of RNA bound to its arginine-rich domain", THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 168, no. 10, 15 May 2002 (2002-05-15), pages 4951 - 4959, XP002354381, ISSN: 0022-1767
 [Y]   SCHEEL BIRGIT ET AL: "Immunostimulating capacities of stabilized RNA molecules", EUROPEAN JOURNAL OF IMMUNOLOGY,, vol. 34, no. 2, 1 January 2004 (2004-01-01), pages 537 - 547, XP002422103, ISSN: 0014-2980, DOI: 10.1002/EJI.200324198

DOI:   http://dx.doi.org/10.1002/eji.200324198
 [A]   JULIO CSAR AGUILAR RUBIDO: "Efecto adyuvante de los antgenos de la superficie y la nucleocpsida del virus de la hepatitis B y su utilidad en el desarrollo de candidatos vacunales.", 1 January 2007 (2007-01-01), XP055385300, Retrieved from the Internet [retrieved on 20170626]
by applicantEP1136077
 EP1346727
 EP0480525
   HILLEMAN, M.R., VACCINE, vol. 19, 2001, pages 1837 - 48
   NASH K., ADV THER, vol. 26, 2009, pages 155 - 169
   YANG N, HEPATOL INT., 12 September 2015 (2015-09-12)
   POL S ET AL., C R ACAD SCI III, vol. 316, 1993, pages 688 - 91
   POL S, J HEPATOL, vol. 34, 2001, pages 917 - 21
   YALCIN K ET AL., INFECTION, vol. 31, 2003, pages 221 - 225
   DIKICI B ET AL., J GASTROENTEROL HEPATOL, vol. 18, no. 2, 2003, pages 218 - 22
   PAGE M ET AL., INTERVIROLOGY, vol. 44, 2001, pages 88 - 97
   YAP I ET AL., ANN ACAD MED SINGAPORE, vol. 25, 1996, pages 120 - 122
   ZUCKERMAN JN ET AL., BMJ, vol. 314, 1997, pages 329
   JONES CD ET AL., VACCINE, vol. 17, no. 20-21, 1999, pages 2528 - 37
   CARMAN WF ET AL., J HEPATOL, vol. 34, 2001, pages 917 - 921
   BERTOLETTI A ET AL., EXPERT REV GASTROENTEROL HEPATOL, vol. 3, no. 5, 2009, pages 561 - 9
   DAHMEN A ET AL., J MED VIROL, vol. 66, 2002, pages 452 - 60
   HORIIKE N ET AL., J CLIN VIROL, vol. 32, 2005, pages 156 - 161
   VANDEPAPELIERE P ET AL., VACCINE, vol. 25, no. 51, 12 December 2007 (2007-12-12), pages 8585 - 97
   PENNA A ET AL., J VIROL, vol. 66, no. 2, 1992, pages 1193 - 6
   NAYERSINA R ET AL., J IMMUNOL, vol. 150, 1993, pages 4659 - 71
   NAGARAJU K ET AL., J VIRAL HEPAT, vol. 4, 1997, pages 221 - 30
   FERRARI C ET AL., J CLIN INVEST, vol. 88, 1991, pages 214 - 22
   MARINOS G ET AL., HEPATOLOGY, vol. 22, 1995, pages 1040 - 9
   TSAI SL ET AL., CLIN INVEST, vol. 89, 1992, pages 87 - 96
   MUZIO V ET AL., BIOTECNOLOGA APLICADA, vol. 18, 2001, pages 103 - 104
   UL-HAQ N ET AL., VACCINE, vol. 21, 2003, pages 3179 - 85
   LOBAINA Y ET AL., MOL IMMUNOL, vol. 63, 2015, pages 320 - 327
   AGUILAR JC ET AL., IMMUNOL CELL BIOL, vol. 82, 2004, pages 539 - 46
   LOBAINA Y ET AL., BIOTECNOLOGA APLICADA, vol. 25, 2008, pages 325 - 331
   CASTRO FO ET AL., INTERFERN Y BIOTECNOLOGA, vol. 6, 1989, pages 251 - 257
   PREZ A ET AL., ACTA BIOTECHNOL, vol. 13, 1993, pages 373 - 383
   IGLESIAS E ET AL., J BIOCHEM MOL BIOL & BIOPHYS, vol. 1, 2001, pages 109 - 122
   GARCIA DIAZ D ET AL., IMMUNOL LETT, vol. 149, 2013, pages 77 - 84
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.